| Code | CSB-RA023991MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to CBS-001, targeting TNFSF14 (Tumor Necrosis Factor Superfamily Member 14), also known as LIGHT. TNFSF14 is a type II transmembrane protein that functions as a critical immunoregulatory cytokine, engaging receptors HVEM (herpesvirus entry mediator) and lymphotoxin-β receptor to modulate T cell activation, costimulation, and inflammatory responses. This molecule plays pivotal roles in immune homeostasis and has been implicated in various pathological conditions including autoimmune diseases, inflammatory disorders, cancer immunity, and transplant rejection. Dysregulated TNFSF14 signaling contributes to chronic inflammation and aberrant immune cell trafficking.
CBS-001 represents a therapeutic antibody designed to modulate TNFSF14-mediated immune responses. This biosimilar provides researchers with a valuable tool for investigating TNFSF14 biology, characterizing receptor-ligand interactions, and exploring therapeutic mechanisms in preclinical disease models. The antibody enables detailed studies of immune checkpoint regulation, T cell biology, and inflammatory pathway modulation across diverse experimental systems.
There are currently no reviews for this product.